<table>
<thead>
<tr>
<th>Project Number</th>
<th>Title</th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>UCI 95-29</td>
<td>Measurement of Breast Tissue Optical Properties (Tromberg)</td>
<td></td>
</tr>
<tr>
<td>UCI 10-24</td>
<td>ATHENA Breast Health Network (Anton-Culver)</td>
<td></td>
</tr>
<tr>
<td>UCI 13-19</td>
<td>Registry Study of Patients Treated with Neoadjuvant Chemotherapy Followed by Mastectomy in Stage I, II, III BREAST CANCER (Daroui)</td>
<td></td>
</tr>
<tr>
<td>UCI 14-25</td>
<td>Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)</td>
<td></td>
</tr>
<tr>
<td>UCI 14-62</td>
<td>Breast Tumor Oxygenation during Exercise (Tromberg)</td>
<td></td>
</tr>
<tr>
<td>UCI 14-81</td>
<td>Mi Salud, Mi Vida: A Self-Discovery Tool for Latina Breast Cancer Survivors (Sorkin)</td>
<td></td>
</tr>
<tr>
<td>UCI 16-01</td>
<td>Pathway Analyses for Individualized Network Therapeutics for Cancer (PAINT Cancer) (Nelson)</td>
<td></td>
</tr>
<tr>
<td><strong>SUSPENDED</strong></td>
<td>UCI 15-64 A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-Conserving Surgery (Lin)</td>
<td></td>
</tr>
<tr>
<td><strong>SUSPENDED</strong></td>
<td>UCI 16-23 Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer [The WISDOM Study (Women Informed to Screen Depending On Measures of Risk)] (Anton-Culver)</td>
<td></td>
</tr>
</tbody>
</table>

**SCREENING / DIAGNOSTIC / EPIDEMIOLOGIC / INTERVENTIONAL**

**CORRELATIVE / OBSERVATIONAL**

For more details contact 1-877-UC-STUDY or ucstudy@uci.edu
Breast Cancer Therapeutic Clinical Trials

**BREAST CANCER**

**Stage I-III**

**UCI 14-67** A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel with Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Mehta)

**Adjuvant**

**HER2- High Risk**

SWOG S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer (Mehta)

**SWOG S1418** Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy (Mehta)

**ALLIANCE A011502** A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial (Mehta)

**Hormone+ High Risk**

**NSABP B51** A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (Darouei)

For more details contact 1-877-UC-STUDY or ucsudy@uci.edu

**opening soon**
Breast Cancer Therapeutic Clinical Trials

UCI 17-90 A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (Ou)

UCI 17-50 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

UCI 16-74 A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine (Carrillo)

Locally Advance / Metastatic

SWOG S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

ECOG EAY131 Molecular Analysis for Therapy Choice (MATCH) (Bota)

NRG BR002 A Phase IIIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (Daroui)

UCI 17-79 Phase 1b/2 Study of SGN-LIV1A in Combination with Pembrolizumab for First-Line Treatment of Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (Parajuli)

**UCI 18-06 A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment (Parajuli)

For more details contact 1-877-UC-STUDY or ucsstudy@uci.edu

**opening soon

0418